Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors

Yiyue Xie; Padmaja Tummala; Aaron J. Oakley; Girdhar Singh Deora; Yuji Nakano; Melissa Rooke; Matthew E. Cuellar; Jessica M. Strasser; Jayme L. Dahlin; Michael A. Walters; Marco G. Casarotto; Philip G. Board; Jonathan B. Baell

doi:10.1021/acs.jmedchem.9b01391

Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors

Yiyue Xie, Padmaja Tummala, Aaron J. Oakley, Girdhar Singh Deora, Yuji Nakano, Melissa Rooke, Matthew E. Cuellar, Jessica M. Strasser, Jayme L. Dahlin, Michael A. Walters, Marco G. Casarotto, Philip G. Board, Jonathan B. Baell

Institute for Therapeutics Discovery and Development

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Glutathione transferase omega-1 (GSTO1-1) is an enzyme whose function supports the activation of interleukin (IL)-1β and IL-18 that are implicated in a variety of inflammatory disease states for which small-molecule inhibitors are sought. The potent reactivity of the active-site cysteine has resulted in reported inhibitors that act by covalent labeling. In this study, structure-activity relationship (SAR) elaboration of the reported GSTO1-1 inhibitor C1-27 was undertaken. Compounds were evaluated for inhibitory activity toward purified recombinant GSTO1-1 and for indicators of target engagement in cell-based assays. As covalent inhibitors, the k_inact/K_I values of selected compounds were determined, as well as in vivo pharmacokinetics analysis. Cocrystal structures of key novel compounds in complex with GSTO1-1 were also solved. This study represents the first application of a biochemical assay for GSTO1-1 to determine k_inact/K_I values for tested inhibitors and the most extensive set of cell-based data for a GSTO1-1 inhibitor SAR series reported to date. Our research culminated in the discovery of 25, which we propose as the preferred biochemical tool to interrogate cellular responses to GSTO1-1 inhibition.

Original language	English (US)
Pages (from-to)	2894-2914
Number of pages	21
Journal	Journal of medicinal chemistry
Volume	63
Issue number	6
DOIs	https://doi.org/10.1021/acs.jmedchem.9b01391
State	Published - Mar 26 2020

Bibliographical note

Funding Information:
The Centre for Drug Candidate Optimization (CDCO) of the Monash Institute of Pharmaceutical Sciences (MIPS) is gratefully acknowledged for testing the kinetic solubility and the metabolic stability of C1-27 and the mice PK of C1-27 , 3d , 22e , and 25 . This work was supported by Project Grant APP1124673 from the National Health and Medical Research Council of Australia (NHMRC) to Philip G. Board, Marco G. Casarotto, and Aaron J. Oakley and by Project Grant APP1156455 from the NHMRC to Jonathan B. Baell, Philip G. Board, Aaron J. Oakley, and Marco G. Casarotto. The NHMRC is also thanked for Fellowship support for Jonathan B. Baell (2012-2016 Senior Research Fellowship No. 1020411, 2017−present Principal Research Fellowship No. 1117602). Acknowledged is the Australian Federal Government Education Investment Fund Super Science Initiative and the Victorian State Government, Victoria Science Agenda Investment Fund for infrastructure support and the facilities, and the scientific and technical assistance of the Australian Translational Medicinal Chemistry Facility (ATMCF), MIPS. ATMCF is supported by Therapeutic Innovation Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program.

Publisher Copyright:
© 2020 American Chemical Society.

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

Publisher link

10.1021/acs.jmedchem.9b01391

Find It

Find It at U of M Libraries

Cite this

Xie, Y., Tummala, P., Oakley, A. J., Deora, G. S., Nakano, Y., Rooke, M., Cuellar, M. E., Strasser, J. M., Dahlin, J. L., Walters, M. A., Casarotto, M. G., Board, P. G., & Baell, J. B. (2020). Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors. Journal of medicinal chemistry, 63(6), 2894-2914. https://doi.org/10.1021/acs.jmedchem.9b01391

@article{5e0a11644aad4bc2ad27b0a4122a898a,

title = "Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors",

abstract = "Glutathione transferase omega-1 (GSTO1-1) is an enzyme whose function supports the activation of interleukin (IL)-1β and IL-18 that are implicated in a variety of inflammatory disease states for which small-molecule inhibitors are sought. The potent reactivity of the active-site cysteine has resulted in reported inhibitors that act by covalent labeling. In this study, structure-activity relationship (SAR) elaboration of the reported GSTO1-1 inhibitor C1-27 was undertaken. Compounds were evaluated for inhibitory activity toward purified recombinant GSTO1-1 and for indicators of target engagement in cell-based assays. As covalent inhibitors, the kinact/KI values of selected compounds were determined, as well as in vivo pharmacokinetics analysis. Cocrystal structures of key novel compounds in complex with GSTO1-1 were also solved. This study represents the first application of a biochemical assay for GSTO1-1 to determine kinact/KI values for tested inhibitors and the most extensive set of cell-based data for a GSTO1-1 inhibitor SAR series reported to date. Our research culminated in the discovery of 25, which we propose as the preferred biochemical tool to interrogate cellular responses to GSTO1-1 inhibition.",

author = "Yiyue Xie and Padmaja Tummala and Oakley, {Aaron J.} and Deora, {Girdhar Singh} and Yuji Nakano and Melissa Rooke and Cuellar, {Matthew E.} and Strasser, {Jessica M.} and Dahlin, {Jayme L.} and Walters, {Michael A.} and Casarotto, {Marco G.} and Board, {Philip G.} and Baell, {Jonathan B.}",

note = "Funding Information: The Centre for Drug Candidate Optimization (CDCO) of the Monash Institute of Pharmaceutical Sciences (MIPS) is gratefully acknowledged for testing the kinetic solubility and the metabolic stability of C1-27 and the mice PK of C1-27 , 3d , 22e , and 25 . This work was supported by Project Grant APP1124673 from the National Health and Medical Research Council of Australia (NHMRC) to Philip G. Board, Marco G. Casarotto, and Aaron J. Oakley and by Project Grant APP1156455 from the NHMRC to Jonathan B. Baell, Philip G. Board, Aaron J. Oakley, and Marco G. Casarotto. The NHMRC is also thanked for Fellowship support for Jonathan B. Baell (2012-2016 Senior Research Fellowship No. 1020411, 2017−present Principal Research Fellowship No. 1117602). Acknowledged is the Australian Federal Government Education Investment Fund Super Science Initiative and the Victorian State Government, Victoria Science Agenda Investment Fund for infrastructure support and the facilities, and the scientific and technical assistance of the Australian Translational Medicinal Chemistry Facility (ATMCF), MIPS. ATMCF is supported by Therapeutic Innovation Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program. Publisher Copyright: {\textcopyright} 2020 American Chemical Society.",

year = "2020",

month = mar,

day = "26",

doi = "10.1021/acs.jmedchem.9b01391",

language = "English (US)",

volume = "63",

pages = "2894--2914",

journal = "Journal of medicinal chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "6",

}

TY - JOUR

T1 - Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors

AU - Xie, Yiyue

AU - Tummala, Padmaja

AU - Oakley, Aaron J.

AU - Deora, Girdhar Singh

AU - Nakano, Yuji

AU - Rooke, Melissa

AU - Cuellar, Matthew E.

AU - Strasser, Jessica M.

AU - Dahlin, Jayme L.

AU - Walters, Michael A.

AU - Casarotto, Marco G.

AU - Board, Philip G.

AU - Baell, Jonathan B.

N1 - Funding Information: The Centre for Drug Candidate Optimization (CDCO) of the Monash Institute of Pharmaceutical Sciences (MIPS) is gratefully acknowledged for testing the kinetic solubility and the metabolic stability of C1-27 and the mice PK of C1-27 , 3d , 22e , and 25 . This work was supported by Project Grant APP1124673 from the National Health and Medical Research Council of Australia (NHMRC) to Philip G. Board, Marco G. Casarotto, and Aaron J. Oakley and by Project Grant APP1156455 from the NHMRC to Jonathan B. Baell, Philip G. Board, Aaron J. Oakley, and Marco G. Casarotto. The NHMRC is also thanked for Fellowship support for Jonathan B. Baell (2012-2016 Senior Research Fellowship No. 1020411, 2017−present Principal Research Fellowship No. 1117602). Acknowledged is the Australian Federal Government Education Investment Fund Super Science Initiative and the Victorian State Government, Victoria Science Agenda Investment Fund for infrastructure support and the facilities, and the scientific and technical assistance of the Australian Translational Medicinal Chemistry Facility (ATMCF), MIPS. ATMCF is supported by Therapeutic Innovation Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program. Publisher Copyright: © 2020 American Chemical Society.

PY - 2020/3/26

Y1 - 2020/3/26

N2 - Glutathione transferase omega-1 (GSTO1-1) is an enzyme whose function supports the activation of interleukin (IL)-1β and IL-18 that are implicated in a variety of inflammatory disease states for which small-molecule inhibitors are sought. The potent reactivity of the active-site cysteine has resulted in reported inhibitors that act by covalent labeling. In this study, structure-activity relationship (SAR) elaboration of the reported GSTO1-1 inhibitor C1-27 was undertaken. Compounds were evaluated for inhibitory activity toward purified recombinant GSTO1-1 and for indicators of target engagement in cell-based assays. As covalent inhibitors, the kinact/KI values of selected compounds were determined, as well as in vivo pharmacokinetics analysis. Cocrystal structures of key novel compounds in complex with GSTO1-1 were also solved. This study represents the first application of a biochemical assay for GSTO1-1 to determine kinact/KI values for tested inhibitors and the most extensive set of cell-based data for a GSTO1-1 inhibitor SAR series reported to date. Our research culminated in the discovery of 25, which we propose as the preferred biochemical tool to interrogate cellular responses to GSTO1-1 inhibition.

AB - Glutathione transferase omega-1 (GSTO1-1) is an enzyme whose function supports the activation of interleukin (IL)-1β and IL-18 that are implicated in a variety of inflammatory disease states for which small-molecule inhibitors are sought. The potent reactivity of the active-site cysteine has resulted in reported inhibitors that act by covalent labeling. In this study, structure-activity relationship (SAR) elaboration of the reported GSTO1-1 inhibitor C1-27 was undertaken. Compounds were evaluated for inhibitory activity toward purified recombinant GSTO1-1 and for indicators of target engagement in cell-based assays. As covalent inhibitors, the kinact/KI values of selected compounds were determined, as well as in vivo pharmacokinetics analysis. Cocrystal structures of key novel compounds in complex with GSTO1-1 were also solved. This study represents the first application of a biochemical assay for GSTO1-1 to determine kinact/KI values for tested inhibitors and the most extensive set of cell-based data for a GSTO1-1 inhibitor SAR series reported to date. Our research culminated in the discovery of 25, which we propose as the preferred biochemical tool to interrogate cellular responses to GSTO1-1 inhibition.

UR - http://www.scopus.com/inward/record.url?scp=85082542472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082542472&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.9b01391

DO - 10.1021/acs.jmedchem.9b01391

M3 - Article

C2 - 32105470

AN - SCOPUS:85082542472

SN - 0022-2623

VL - 63

SP - 2894

EP - 2914

JO - Journal of medicinal chemistry

JF - Journal of medicinal chemistry

IS - 6

ER -

Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors

Abstract

Bibliographical note

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this